A majority of AML cell lines and clinical samples had the unmethylated state of B7-H3 gene promoter, and no significant difference in B7-H3 unmethylation level between AML patients and controls (P = 0.597, Figure 8(a)). This evidence concerns the gene CD276 and acute myeloid leukemia.